BiotechTube
Home/Restem/Andres Isaias
AI

Andres Isaias

Chief Executive Officer

Restem

Therapeutic Areas

Autoimmune DisordersNeurological DisordersAge-related Diseases

Restem Pipeline

DrugIndicationPhase
Restem-LIdiopathic Inflammatory Myopathy (IIM)Phase 2/3
Restem-x (aNK)Age-related Diseases / Cellular SenescenceUnknown

Leadership Team at Restem

RG
Rafael Gonzalez, PhD
Chief Development & Science Officer
View full Restem profile